Our client SciRhom has closed its Series A financing round with a mere 63 mn Euros

Our client SciRhom has closed its Series A financing round with a mere 63 mn Euros. SciRhom's antibody has the potential to rewrite the success story of anti TNFalpha antibodies. Our firm has developed, with SciRhom, a patent strategy from scratch, which turned out to be succesful in all aspects. Surely, while working for startups like SciRhom requires an extraordinary level of commitment and passion, the feeling that our work doesn't only cost client's money, but helps them to actually raise money, is unbeatable!”